Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6096532 | 0.83 | SMN1; SMN2 (0.56) | SMN1; SMN2CYP1A2CRHR1 | |
| SCHEMBL6099027 | 0.83 | SMN1; SMN2 (0.53) | SMN1; SMN2CYP1A2CRHR1POLBTDP1 | |
| SCHEMBL6097890 | 0.80 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2CRHR1MAPK1 | |
| SCHEMBL6096391 | 0.80 | POLB (0.41) | SMN1; SMN2CYP1A2POLB | |
| SCHEMBL6096477 | 0.75 | PTGER4 (0.51) | SMN1; SMN2POLBTDP1 | |
| SCHEMBL31490068 | 0.73 | CA2 (0.55) | SMN1; SMN2CYP1A2POLB | |
| SCHEMBL2959929 | 0.73 | CA2 (0.55) | SMN1; SMN2CYP1A2POLB | |
| SCHEMBL6098438 | 0.72 | ALOX5 (0.35) | CYP1A2PTGS2MAPK1POLBTDP1 | |
| SCHEMBL6094995 | 0.70 | PTGS2 (0.41) | CYP1A2PTGS2POLB | |
| SCHEMBL6173067 | 0.68 | SMN1; SMN2 (0.57) | SMN1; SMN2CRHR1POLBPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7001917-B2 | Pyrazole compounds as anti-inflammatory and analgesic agents | WARNER LAMBERT COMPANY LLC (US) | 2006-02-21 | — | — | US | disclosed |
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | HIRANO MISATO (JP) | 2004-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040019045-A1 | 2-(4-(4-(4-Fluorophenyl)-3,5-imethyl-1H-pyrazol-1-yl)phenyl) ethyl (4-methylphenyl)sulfonylcarbamate ammonium salt, e.g., as an antagonist for Prostoglandin E receptor; analgesics; antipyretics; antiinflammatory agents | PTGER1, PTGS1, PTGIR | SMN1; SMN2 4491/4885CYP1A2 670/4885PTGS2 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.